CONMED Weighs Strategic Sale as Takeover Interest Emerges
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.
No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation.
A whistleblower has accused Medicare Advantage insurer Alignment Healthcare of misclassifying expenses to inflate earnings.
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
The unit, once a pandemic star, attracts strong private equity interest.
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.